Physician profile
Stephen Ellison
NPI 1316395445
$4,423.83
in general payments reported to CMS, 2019-2025
27 companies · $984 in 2025
The $984 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2020: $396 · 2021: $622 · 2022: $619 · 2023: $538 · 2024: $949 · 2025: $984.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,347 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,347.28 |
| Education | $123.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,635.92 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $459.09 | 2024-2025 | Xdemvy |
| Allergan, INC. | $354.93 | 2019-2021 | |
| Harrow Eye, LLC | $210.92 | 2024-2025 | Vevye |
| Bausch & Lomb Americas INC. | $191.12 | 2022-2024 | Miebo, Xiidra, Scoutpro Osmolarity System |
| Alcon Vision LLC | $177.74 | 2021-2025 | Tryptyr |
| Oyster Point Pharma, INC. | $171.39 | 2022-2025 | Tyrvaya |
| Dompe US, INC. | $158.57 | 2022-2025 | Oxervate |
| Mallinckrodt Hospital Products INC. | $148.63 | 2024-2025 | Acthar |
| Coopervision INC. | $108.06 | 2019-2023 | Misight Contact Lens |
| Amgen INC. | $104.35 | 2024-2025 | Tepezza |
| Johnson & Johnson Vision Care, INC. | $100.00 | 2024 | Acuvue |
| Abbvie INC. | $99.27 | 2023-2025 | |
| New World Medical,INC. | $97.23 | 2019-2023 | |
| Biotissue Holdings INC. | $70.11 | 2019-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $65.51 | 2022-2024 | Tecnis Iol, Tecnis Simplicity, Tecnis Iol |
| Glaukos Corporation | $63.10 | 2024-2025 | Radius, Idosetr |
| Novartis Pharmaceuticals Corporation | $33.59 | 2020-2023 | |
| Horizon Therapeutics Plc | $28.86 | 2023 | Tepezza |
| Shire North American Group INC | $23.85 | 2019 | |
| Aerie Pharmaceuticals, INC. | $20.41 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Lensar, INC. | $18.09 | 2023 | Lensar Laser System |
| Sight Sciences, INC. | $17.70 | 2022 | |
| Eyevance Pharmaceuticals LLC | $16.57 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.39 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $13.03 | 2023 | Iolmaster 700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Ellison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.